Dr. Lauren Silverman is a Managing Director of the Novartis Option Fund in Cambridge, Massachusetts, USA. Prior to joining the Option Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology after having been a founding scientist of Cadus Pharmaceuticals. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah. She is the author of 12 scientific publications and 4 patents. Lauren currently serves on the boards of Ascent Therapeutics, Proteostasis Therapeutics and Cequent Pharmaceuticals.
